IL-17 in Chronic Inflammation: From Discovery to Targeting

被引：349

作者：

Beringer, Audrey ^{[1
]}

Noack, Melissa ^{[1
]}

Miossec, Pierre ^{[1
]}

机构：

[1] Univ Lyon, Dept Immunol & Rheumatol, Immunogen & Inflammat Res Unit, EA 4130, Lyon, France

来源：

TRENDS IN MOLECULAR MEDICINE | 2016年 / 22卷 / 03期

关键词：

ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; T-CELL; HOST-DEFENSE; PHASE-II; PSORIATIC-ARTHRITIS; MULTIPLE-SCLEROSIS; DISEASE-ACTIVITY;

D O I：

10.1016/j.molmed.2016.01.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Interleukin-17 (IL-17) is a cytokine which elicits protection against extracellular bacterial and fungal infections and which plays important roles in inflammation. However, when produced in excess, it contributes to chronic inflammation associated with many inflammatory and autoimmune disorders. This has made 1L-17 an attractive therapeutic target. The present review describes the structure of the IL-17 family, the IL-17 receptor complex, and the cells producing IL-17. The contributions of IL-17 to disease as well as new IL-17-based treatment options are discussed. Finally, the results of IL-17 or IL-17 receptor inhibitors in clinical trials are detailed. With a fruitful outlook, drug registration has now been granted for psoriasis psoriatic arthritis and ankylosing spondylitis, and also bears great potential in a growing number of conditions.

引用

页码：230 / 241

页数：12

共 103 条

[31] Structure and signalling in the IL-17 receptor family [J].

Gaffen, Sarah L. .

NATURE REVIEWS IMMUNOLOGY, 2009, 9 (08) :556-567

[32] LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study [J].

Genovese, M. C. ;

Van den Bosch, F. ;

Roberson, S. A. ;

Bojin, S. ;

Biagini, I. M. ;

Ryan, Peter ;

Sloan-Lancaster, J. .

ARTHRITIS AND RHEUMATISM, 2010, 62 (04) :929-939

[33] A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors [J].

Genovese, Mark C. ;

Greenwald, Maria ;

Cho, Chul-Soo ;

Berman, Alberto ;

Jin, Ling ;

Cameron, Gregory S. ;

Benichou, Olivier ;

Xie, Li ;

Braun, Daniel ;

Berclaz, Pierre-Yves ;

Banerjee, Subhashis .

ARTHRITIS & RHEUMATOLOGY, 2014, 66 (07) :1693-1704

[34] One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study [J].

Genovese, Mark C. ;

Durez, Patrick ;

Richards, Hanno B. ;

Supronik, Jerzy ;

Dokoupilova, Eva ;

Aelion, Jacob A. ;

Lee, Sang-Heon ;

Codding, Christine E. ;

Kellner, Herbert ;

Ikawa, Takashi ;

Hugot, Sophie ;

Ligozio, Gregory ;

Mpofu, Shephard .

JOURNAL OF RHEUMATOLOGY, 2014, 41 (03) :414-421

[35] Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study [J].

Genovese, Mark C. ;

Durez, Patrick ;

Richards, Hanno B. ;

Supronik, Jerzy ;

Dokoupilova, Eva ;

Mazurov, Vadim ;

Aelion, Jacob A. ;

Lee, Sang-Heon ;

Codding, Christine E. ;

Kellner, Herbert ;

Ikawa, Takashi ;

Hugot, Sophie ;

Mpofu, Shephard .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (06) :863-869

[36] A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis [J].

Gordon, Kenneth B. ;

Duffin, Kristina Callis ;

Bissonnette, Robert ;

Prinz, Joerg C. ;

Wasfi, Yasmine ;

Li, Shu ;

Shen, Yaung-Kaung ;

Szapary, Philippe ;

Randazzo, Bruce ;

Reich, Kristian .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :136-144

[37] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials [J].

Griffiths, Christopher E. M. ;

Reich, Kristian ;

Lebwohl, Mark ;

van de Kerkhof, Peter ;

Paul, Carle ;

Menter, Alan ;

Cameron, Gregory S. ;

Erickson, Janelle ;

Zhang, Lu ;

Secrest, Roberta J. ;

Ball, Susan ;

Braun, Daniel K. ;

Osuntokun, Olawale O. ;

Heffernan, Michael P. ;

Nickoloff, Brian J. ;

Papp, Kim .

LANCET, 2015, 386 (9993) :541-551

[38] Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab [J].

Grosskreutz, Cynthia L. ;

Hockey, Hans-Ulrich ;

Serra, Denise ;

Dryja, Thaddeus P. .

CORNEA, 2015, 34 (12) :1551-1556

[39] IL-17 enhances chemokine gene expression through mRNA stabilization [J].

Hartupee, Justin ;

Liu, Caini ;

Novotny, Michael ;

Li, Xiaoxia ;

Hamilton, Thomas .

JOURNAL OF IMMUNOLOGY, 2007, 179 (06) :4135-4141

[40] DISCOVERY AND CHARACTERIZATION OF ABT-122, AN ANTI-TNF/IL-17 DVD-IG™ MOLECULE AS A POTENTIAL THERAPEUTIC CANDIDATE FOR RHEUMATOID ARTHRITIS [J].

Hsieh, C. -M. ;

Cuff, C. ;

Tarcsa, E. ;

Hugunin, M. .

ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 :495-495

← 1 2 3 4 5 6 7 8 9 10 →